NDA 218881 · Eli Lilly and CO
Inluriyo
Imlunestrant Tosylate · Oral · Estrogen Receptor Antagonist
NovelCDER novel approval, Sep 25, 2025: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Sep 25, 2025
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
21
2 Phase 3, 7 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Therapeutic areas: Oncology · Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Imlunestrant" as an intervention, any sponsor and status, largest first.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05514054 · 8,000 participants (planned) · Start Oct 4, 2022 · Primary completion Oct 2027
Drug: Imlunestrant; Tamoxifen and 3 more · For: Breast Neoplasms
Sites: Daphne, Alabama; Huntsville, Alabama; Mobile, Alabama · 672 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT05768139 · 880 participants (planned) · Start Apr 17, 2023 · Primary completion Jul 2030
Drug: STX-478; Fulvestrant and 9 more · For: Breast Cancer; Solid Tumors, Adult
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 65 sites in all
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04975308 · 874 participants · Start Oct 4, 2021 · Primary completion Jun 24, 2024
Drug: Imlunestrant; Exemestane and 2 more · For: Breast Neoplasms; Neoplasm Metastasis
Sites: Chandler, Arizona; Gilbert, Arizona; Greenbrae, California · 243 sites in all
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07287098 · 600 participants (planned) · Start May 13, 2026 · Primary completion Jan 2029
Drug: Imlunestrant; Goserelin and 1 more · For: Breast Neoplasms
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 90 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07114601 · 421 participants (planned) · Start Aug 6, 2025 · Primary completion Apr 2030
Drug: LY4257496; Standard of Care Anticancer Therapies · For: Breast Neoplasms; Colorectal Neoplasms; Prostate Neoplasm and 4 more
Sites: Duarte, California; Santa Monica, California; Stanford, California · 33 sites in all
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04188548 · 379 participants · Start Dec 10, 2019 · Primary completion Jun 29, 2020
Drug: LY3484356; Abemaciclib and 5 more · For: Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer and 1 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Springdale, Arkansas · 74 sites in all
- A Study of Imlunestrant (LY3484356) in Healthy Female ParticipantsPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07918859 · 343 participants (planned) · Start Nov 2026 · Primary completion Aug 2027
Drug: Imlunestrant (Test); Imlunestrant (Reference) and 1 more · For: Healthy
Sites: South Miami, Florida; Lenexa, Kansas; Springfield, Missouri · 5 sites in all
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05307705 · 260 participants (planned) · Start May 11, 2022 · Primary completion Apr 2, 2025
Drug: LOXO-783; Fulvestrant and 4 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 50 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
Jhaveri KL, Neven P, Casalnuovo ML, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.
Jhaveri KL, Neven P, Casalnuovo ML, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Jhaveri KL, Lim E, Jeselsohn R, et al. · J Clin Oncol 2024 · Clinical Trial, Phase I, Multicenter Study
- Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Yonemori K, Boni V, Min KG, et al. · Gynecol Oncol 2024 · Clinical Trial, Phase I, Randomized Controlled Trial
- Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
Bhave M, Jhaveri KL, Kaufman PA, et al. · Breast Cancer Res 2025 · Randomized Controlled Trial, Clinical Trial, Phase I
- Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open-Label Study.
Datta-Mannan A, Czeskis B, Shanks E, et al. · Clin Pharmacol Drug Dev 2025 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.